Global Anti-Tobacco Summit Targets Youth Nicotine Addiction ‘Epidemic’ and Environmental Harms 13/11/2025 Felix Sassmannshausen GENEVA – Global health leaders are calling for robust new measures to combat the use of tobacco and related products, including restrictions on flavours to curb the surge in e-cigarettes use in adolescents and filter bans to protect the environment. These and other proposals will be debated over the next two weeks as over 1,400 […] Continue reading -> New Malaria Drug Candidate Exceeds Cure Rate for Standard ACTs in Phase 3 Trial 12/11/2025 Felix Sassmannshausen The 97% cure rate for the novel compound, ganaplacide/lumefantrine in a recent Phase 3 trial offers hope for continued progress rolling back malaria even as resistance to artemisinin combination therapies (ACT) escalates. A next-generation antimalarial drug GanLum (ganaplacide/lumefantrine, KLU156) slightly outperformed a standard of care Artemisinin Combination Therapy (ACT) in a recent Phase 3 trial […] Continue reading -> Looming Malaria Drug Resistance Spurs Global Search for New Treatments 10/10/2025 Felix Sassmannshausen Malaria affects millions worldwide, and progress against the disease is stalling. Emerging drug resistance threatens to reverse hard-won gains, putting many more lives at risk. Public–private partnerships are racing to close the treatment gap before the current drugs begin to fail. “We believe that the eradication of malaria is in sight, but it’s an ongoing […] Continue reading -> This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
New Malaria Drug Candidate Exceeds Cure Rate for Standard ACTs in Phase 3 Trial 12/11/2025 Felix Sassmannshausen The 97% cure rate for the novel compound, ganaplacide/lumefantrine in a recent Phase 3 trial offers hope for continued progress rolling back malaria even as resistance to artemisinin combination therapies (ACT) escalates. A next-generation antimalarial drug GanLum (ganaplacide/lumefantrine, KLU156) slightly outperformed a standard of care Artemisinin Combination Therapy (ACT) in a recent Phase 3 trial […] Continue reading -> Looming Malaria Drug Resistance Spurs Global Search for New Treatments 10/10/2025 Felix Sassmannshausen Malaria affects millions worldwide, and progress against the disease is stalling. Emerging drug resistance threatens to reverse hard-won gains, putting many more lives at risk. Public–private partnerships are racing to close the treatment gap before the current drugs begin to fail. “We believe that the eradication of malaria is in sight, but it’s an ongoing […] Continue reading -> This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Looming Malaria Drug Resistance Spurs Global Search for New Treatments 10/10/2025 Felix Sassmannshausen Malaria affects millions worldwide, and progress against the disease is stalling. Emerging drug resistance threatens to reverse hard-won gains, putting many more lives at risk. Public–private partnerships are racing to close the treatment gap before the current drugs begin to fail. “We believe that the eradication of malaria is in sight, but it’s an ongoing […] Continue reading ->